Clinical Trials Logo

Pathologic Residual Cancer Cells clinical trials

View clinical trials related to Pathologic Residual Cancer Cells.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT03703427 Not yet recruiting - Clinical trials for Pathologic Residual Cancer Cells

Capecitabine Versus Vinorelbine in High Risk Breast Cancer With Pathologic Residual Tumors After Preoperative Chemotherapy

Start date: November 2018
Phase: Phase 2
Study type: Interventional

This study is designed to investigate the efficacy and safety of capecitabine versus vinorelbine as a postoperative adjuvant chemotherapy, for high risk breast cancer patients who have pathologic residual cancer cells after the preoperative chemotherapy.